Expression of Concern: Potential Tumor Suppressor NESG1 as an Unfavorable Prognosis Factor in Nasopharyngeal Carcinoma (PLoS ONE (2011) 6:11 (e27887) DOI: 10.1371/journal.pone.0027887);Potential tumor suppressor NESG1 as an unfavorable prognosis factor in nasopharyngeal carcinoma

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Liu, Zhen ^a,b   Luo, Weiren ^b,c   Zhou, Ying ^b   Zhen, Yan ^b   Yang, Huiling ^c   Yu, Xiaoli ^b   Ye, Yanfen ^b   Li, Xin ^b   Wang, Hao ^b   Jiang, Qinping ^a   Zhang, Yajie ^a   Yao, Kaitai ^b   Fang, Weiyi ^b  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c GUANGDONG MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

LENTIVIRUS VECTOR; MITOGEN ACTIVATED PROTEIN KINASE; NASOPHARYNGEAL EPITHELIUM SPECIFIC PROTEIN 1; PROTEIN P21; SHORT HAIRPIN RNA; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; CCDC19 PROTEIN, HUMAN; CCNA1 PROTEIN, HUMAN; CYCLIN A1; CYCLIN DEPENDENT KINASE INHIBITOR 1A; PROTEIN;

ADULT; ARTICLE; CANCER INHIBITION; CANCER INVASION; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE REGULATION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA METHYLATION; DOWN REGULATION; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERPLASIA; INTRACELLULAR SIGNALING; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; NASOPHARYNX CARCINOMA; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; AGED; CELL MOTION; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; NASOPHARYNX TUMOR; PATHOLOGY; PROMOTER REGION; PROPORTIONAL HAZARDS MODEL; REGRESSION ANALYSIS; REPRODUCIBILITY; SIGNAL TRANSDUCTION;

AGED; CELL MOVEMENT; CELL PROLIFERATION; CYCLIN A1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DNA METHYLATION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPERPLASIA; MALE; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; MULTIVARIATE ANALYSIS; NASOPHARYNGEAL NEOPLASMS; NEOPLASM INVASIVENESS; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROPORTIONAL HAZARDS MODELS; PROTEINS; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS;

EID: 82155164155     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0231298     Document Type: Erratum

References (32)

1. Cho WC, (2007) Nasopharyngeal carcinoma: molecular biomarker discovery and progress. Mol Cancer 6: 1.
2. Fang W, Li X, Jiang Q, Liu Z, Yang H, et al. (2008) Transcriptional patterns, biomarkers and pathways characterizing nasopharyngeal carcinoma of Southern China. J Transl Med 6: 32.
3. Du ZM, Hu LF, Wang HY, Yan LX, Zeng YX, et al. (2011) Upregulation of MiR-155 in nasopharyngeal carcinoma is partly driven by LMP1 and LMP2A and downregulates a negative prognostic marker JMJD1A. PLoS One 6: e19137.
4. Wang S, Fang W, (2011) Increased expression of hepatoma-derived growth factor correlates with poor prognosis in human nasopharyngeal carcinoma. Histopathology 58: 217-224.
5. Lung HL, Cheung AK, Cheng Y, Kwong FM, Lo PH, et al. (2010) Functional characterization of THY1 as a tumor suppressor gene with antiinvasive activity in nasopharyngeal carcinoma. Int J Cancer 127: 304-312.
6. Song LB, Li J, Liao WT, Feng Y, Yu CP, et al. (2009) The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. J Clin Invest 119: 3626-3636.
7. Cui Y, Ying Y, van Hasselt A, Ng KM, Yu J, et al. (2008) OPCML is a broad tumor suppressor for multiple carcinomas and lymphomas with frequently epigenetic inactivation. PLoS One 3: e2990.
8. Li Z, Yao K, Cao Y, (1999) Molecular cloning of a novel tissue-specific gene from human nasopharyngeal epithelium. Gene 237: 235-240.
9. Liu Z, Li X, He X, Jiang Q, Xie S, et al. (2011) Decreased expression of updated NESG1 in nasopharyngeal carcinoma: Its potential role and preliminarily functional mechanism. Int J Cancer 128: 2562-2571.
10. Zhou Y, Zeng Z, Zhang W, Xiong W, Wu M, et al. (2008) Lactotransferrin: a candidate tumor suppressor-Deficient expression in human nasopharyngeal carcinoma and inhibition of NPC cell proliferation by modulating the mitogen-activated protein kinase pathway. Int J Cancer 123: 2065-2072.
11. Bhandari DR, Seo KW, Roh KH, Jung JW, Kang SK, et al. (2010) REX-1 expression and p38 MAPK activation status can determine proliferation/differentiation fates in human mesenchymal stem cells. PLoS One 5: e10493.
12. Jonak C, Mildner M, Klosner G, Paulitschke V, Kunstfeld R, et al. (2011) The hsp27kD heat shock protein and p38-MAPK signaling are required for regular epidermal differentiation. J Dermatol Sci 61: 32-37.
13. Jadeski LC, Chakraborty C, Lala PK, (2003) Nitric oxide-mediated promotion of mammary tumour cell migration requires sequential activation of nitric oxide synthase, guanylate cyclase and mitogen-activated protein kinase. Int J Cancer 106: 496-504.
14. Ungefroren H, Schniewind B, Groth S, Chen WB, Müerköster SS, et al. (2007) Antitumor activity of ALK1 in pancreatic carcinoma cells. Int J Cancer 120: 1641-1651.
15. Langlois B, Perrot G, Schneider C, Henriet P, Emonard H, et al. (2010) LRP-1 promotes cancer cell invasion by supporting ERK and inhibiting JNK signaling pathways. PLoS One 5: e11584.
16. Recio JA, Merlino G, (2002) Hepatocyte growth factor/scatter factor activates proliferation in melanoma cells through p38 MAPK, ATF-2 and cyclin D1. Oncogene 21: 1000-1008.
17. Knippen S, Löning T, Müller V, Schröder C, Jänicke F, et al. (2009) Expression and prognostic value of activating transcription factor 2 (ATF2) and its phosphorylated form in mammary carcinomas. Anticancer Res 29: 183-189.
18. Zoumpourlis V, Papassava P, Linardopoulos S, Gillespie D, Balmain A, et al. (2000) High levels of phosphorylated c-Jun, Fra-1, Fra-2 and ATF-2 proteins correlate with malignant phenotypes in the multistage mouse skin carcinogenesis model. Oncogene 19: 4011-4021.
19. Johansen C, Vestergaard C, Kragballe K, Kollias G, Gaestel M, et al. (2009) MK2 regulates the early stages of skin tumor promotion. Carcinogenesis 30: 2100-2108.
20. Manke IA, Nguyen A, Lim D, Stewart MQ, Elia AE, et al. (2005) MAPKAP kinase-2 is a cell cycle checkpoint kinase that regulates the G2/M transition and S phase progression in response to UV irradiation. Mol Cell 17: 37-48.
21. Reinhardt HC, Aslanian AS, Lees JA, Yaffe MB, (2007) p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell 11: 175-189.
22. Reinhardt HC, Aslanian AS, Lees JA, Yaffe MB, (2010) p38 mitogen-activated protein kinase-driven MAPKAPK2 regulates invasion of bladder cancer by modulation of MMP-2 and MMP-9 activity. Cancer Res 70: 832-841.
23. Henkens R, Delvenne P, Arafa M, Moutschen M, Zeddou M, et al. (2008) Cervix carcinoma is associated with an up-regulation and nuclear localization of the dual-specificity protein phosphatase VHR. BMC Cancer 8: 147.
24. Rahmouni S, Cerignoli F, Alonso A, Tsutji T, Henkens R, et al. (2006) Loss of the VHR dual-specific phosphatase causes cell-cycle arrest and senescence. Nat Cell Biol 8: 524-531.
25. Modi H, Li L, Chu S, Rossi J, Yee JK, et al. (2011) Inhibition of Grb2 expression demonstrates an important role in BCR-ABL-mediated MAPK activation and transformation of primary human hematopoietic cells. Leukemia 25: 305-312.
26. Haines E, Minoo P, Feng Z, Resalatpanah N, Nie XM, et al. (2009) Tyrosine phosphorylation of Grb2: role in prolactin/epidermal growth factor cross talk in mammary epithelial cell growth and differentiation. Mol Cell Biol 29: 2505-2520.
27. Rauhala HE, Jalava SE, Isotalo J, Bracken H, Lehmusvaara S, et al. (2010) miR-193b is an epigenetically regulated putative tumor suppressor in prostate cancer. Int J Cancer 127: 1363-7132.
28. Dong W, Chen X, Xie J, Sun P, Wu Y, (2010) Epigenetic inactivation and tumor suppressor activity of HAI-2/SPINT2 in gastric cancer. Int J Cancer 127: 1526-1534.
29. Cui Y, Ying Y, van Hasselt A, Ng KM, Yu J, et al. (2008) OPCML is a broad tumor suppressor for multiple carcinomas and lymphomas with frequently epigenetic inactivation. PLoS One 3 (8): e2990.
30. Poage GM, Christensen BC, Houseman EA, McClean MD, Wiencke JK, et al. (2010) Genetic and epigenetic somatic alterations in head and neck squamous cell carcinomas are globally coordinated but not locally targeted. PLoS One 5 (3): e9651.
31. Wu A, Wu B, Guo J, Luo W, Wu D, et al. (2011) Elevated expression of CDK4 in lung cancer. J Transl Med 9: 38.
32. Koga Y, Pelizzola M, Cheng E, Krauthammer M, Sznol M, et al. (2009) Genome-wide screen of promoter methylation identifies novel markers in melanoma. Genome Res 19: 1462-1470.